Nivolumab is commonly used for the treatment of renal cell carcinoma (RCC) due to the efficacy seen in past trials, including CheckMate 025 and CheckMate 214. Standard-of-care treatment for patients with intermediate- to high-risk RCC consists of partial or radical nephrectomy and surveillance, but a recent study by Mohamad E. Allaf, MD, and colleagues compared the use of nivolumab before nephrectomy followed by adjuvant nivolumab with surgery only in patients with high-risk RCC to determine which ...
Localized Renal Cell Carcinoma
Advertisement
Latest News
Dr. Albiges breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial.
Researchers analyzed the connection between the outcomes and specific predictors of interest.
Previous studies investigating adjuvant therapy in patients with RCC have not included those with PSM.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
Advertisement
Knowledge Hub Spotlight
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Advertisement
Advertisement
Latest News
A recent study assessed pathologic and short-term oncological and survival outcomes of prostate cancer surgical approaches.
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.